Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313768 · ClinicalTrials.gov registry record · Phase 2
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00313768 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 23 participants.
The verdict
NCT00313768, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Interventions
- DRUG paclitaxel + carboplatin + bevacizumab
- DRUG carboplatin + paclitaxel + bevacizumab + PF-3512676
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313768
The ClinicalTrials.gov registry entry for NCT00313768 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel + carboplatin + bevacizumab is the first listed.
NCT00313768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313768 about?
NCT00313768 is a clinical study titled "Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC". To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
What is the current status of trial NCT00313768?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2005-12. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00313768?
The interventions under investigation include: paclitaxel + carboplatin + bevacizumab (DRUG), carboplatin + paclitaxel + bevacizumab + PF-3512676 (DRUG).
Who is sponsoring clinical trial NCT00313768?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.